BioPlus Co Ltd
KOSDAQ:099430
BioPlus Co Ltd
Long-Term Debt
BioPlus Co Ltd
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioPlus Co Ltd
KOSDAQ:099430
|
Long-Term Debt
₩2.7B
|
CAGR 3-Years
95%
|
CAGR 5-Years
127%
|
CAGR 10-Years
N/A
|
|
|
Suheung Co Ltd
KRX:008490
|
Long-Term Debt
₩126.2B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-2%
|
|
|
SD Biosensor Inc
KRX:137310
|
Long-Term Debt
₩599.4B
|
CAGR 3-Years
220%
|
CAGR 5-Years
193%
|
CAGR 10-Years
N/A
|
|
|
H
|
HLB Inc
KOSDAQ:028300
|
Long-Term Debt
₩51.5B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
91%
|
CAGR 10-Years
N/A
|
|
|
O
|
Optus Pharmaceutical Co Ltd
KOSDAQ:131030
|
Long-Term Debt
₩593.2m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
T
|
T&L Co Ltd
KOSDAQ:340570
|
Long-Term Debt
₩299.7m
|
CAGR 3-Years
32%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
BioPlus Co Ltd
Glance View
BioPlus Co., Ltd. is engaged in the manufacturing and supplying of diverse dermal fillers. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2021-09-27. The firm is engaged in the production and sale of biomaterials for tissue restoration used for temporary improvement of facial wrinkles, namely hyaluronic acid fillers. In addition, the Company is engaged in the production and sale of anti-adhesion agents that reduce the formation of adhesions in surgical areas, biomaterials for joint tissue repair, and other products.
See Also
What is BioPlus Co Ltd's Long-Term Debt?
Long-Term Debt
2.7B
KRW
Based on the financial report for Dec 31, 2024, BioPlus Co Ltd's Long-Term Debt amounts to 2.7B KRW.
What is BioPlus Co Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
127%
Over the last year, the Long-Term Debt growth was -69%. The average annual Long-Term Debt growth rates for BioPlus Co Ltd have been 95% over the past three years , 127% over the past five years .
